Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

3.830 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q2 2024
JAGX stock results show that Jaguar Health missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Jaguar Health (JAGX) Stock Is Down 15%
Jaguar Health shares are trading lower by 15.4% during Tuesday's session. The company reported worse-than-expected second-quarter results. 
Via Benzinga
Jaguar Health Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Via ACCESSWIRE
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful
Via ACCESSWIRE
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Via ACCESSWIRE
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
Via ACCESSWIRE
Why Jaguar Health Stock Is Crashing
Jaguar Health shares are falling Tuesday after the company announced its phase 3 OnTarget trial did not meet its primary endpoint. Here's a look at the details: 
Via Benzinga
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
Via ACCESSWIRE
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
Via ACCESSWIRE
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Via Benzinga
Why Is Azitra (AZTR) Stock Up 315% Today?
Azitra stock is up on Tuesday alongside heavy trading of AZTR shares after it provided investors with an update on new patents. 
Via InvestorPlace
Spot Ethereum ETFs: 9 Tickers to Watch as New Funds Start Trading
Spot Ethereum ETFs have started trading on Tuesday marking a major milestone for fans of the crypto and Ethereum blockchain. 
Via InvestorPlace
Topics ETFs
Why Is Serve Robotics (SERV) Stock Down Today?
Serve Robotics stock is down on Tuesday after the company revealed the pricing of warrants for SERV shares in a private placement. 
Via InvestorPlace
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Via ACCESSWIRE
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
Jaguar Health stock is down on Tuesday as JAGX investors react to failed results from a Phase 3 clinical trial of crofelemer. 
Via InvestorPlace
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
Via Benzinga
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Via ACCESSWIRE
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Via ACCESSWIRE
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
Via ACCESSWIRE
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV
Via AB Newswire
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Via ACCESSWIRE
Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
Via ACCESSWIRE
What's Going On With Jaguar Health Stock?
Jaguar Health shares are falling after the stock effected a reverse split at an exchange ratio of 1-for-60 Thursday, in order to support the company's compliance with Nasdaq listing standards. 
Via Benzinga
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.